CTXR News & Events

Citius Pharmaceuticals has received $3.8M in non-dilutive capital through New Jersey's Technology Business Tax Certificate Transfer Program, more commonly known as the Net Operating Loss Program, funded through the New Jersey Economic Development Authority, or NJEDA.

Revenue of $3.9M during the quarter ended December 31, 2025 reflects sales related to the launch of Lymphir. Cash and cash equivalents totaled $7.3M as of December 31, 2025 .

Q1 consolidated revenue was $3.9M, reflecting initial U.S. sales of Lymphir at Citius Oncology (CTOR). Cash and cash equivalents totaled $7.7M as of December 31, 2025.

Citius Pharmaceuticals (CTXR) reported business and financial results for the fiscal first quarter ended December 31, 2025, and provided a business update, including progress at its majority-owned subsidiary, Citius Oncology (CTOR). "I am thrilled to report that we have successfully transitioned to a revenue generating company following Citius Oncology's December 2025 launch of Lymphir. We recorded $3.9 million in revenue during the quarter, reflecting the initial sales at Citius Oncology's nationwide network of distributors. This milestone is the result of years of focused execution designed to translate innovation into tangible value for the cutaneous T-cell community and Citius stakeholders alike. I congratulate the entire Citius team on an outstanding effort to bring Lymphirto market," said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharma.